{"id":"eprozinol","rwe":[{"pmid":"4026148","year":"1985","title":"[Convulsions with 3 antitussive substituted derivatives of piperazine (zipeprol, eprazinone, eprozinol)].","finding":"","journal":"Annales de pediatrie","studyType":"Clinical Study"},{"pmid":"7312935","year":"1981","title":"Mechanisms of anti-bronchoconstrictive effects of eprozinol. II. In vivo studies on the guinea pig.","finding":"","journal":"Pharmacology","studyType":"Clinical Study"},{"pmid":"6171839","year":"1981","title":"Mechanisms of anti-bronchoconstrictive effects of eprozinol. I. In vitro studies.","finding":"","journal":"Pharmacology","studyType":"Clinical Study"},{"pmid":"756799","year":"1978","title":"[Eprozinol treatment of chronic bronchitis with dyspnea and cough].","finding":"","journal":"Broncho-pneumologie","studyType":"Clinical Study"},{"pmid":"21982","year":"1977","title":"Dualist or pseudo-dualist interactions of mepyramine, diphenhydramine and eprozinol with histamine at H1-receptors.","finding":"","journal":"Japanese journal of pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"eprozinol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"R03DX02","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"eupneron","offLabel":[],"synonyms":["eprozinol","eupneron","eprozinol dihydrochloride"],"timeline":[],"approvals":[],"brandName":"Eupneron","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"eprozinol","explanation":"Imagine your body's cells are like locks, and enzymes or receptors are like keys that fit into those locks. Eprozinol is like a key that blocks the action of another key, preventing it from unlocking the cell and causing a problem. This can help to reduce inflammation and other symptoms associated with certain diseases.","oneSentence":"Eprozinol is thought to work by inhibiting a specific enzyme or receptor, but the exact details of its mechanism are not well understood.","technicalDetail":"Eprozinol is a competitive inhibitor of a specific enzyme or receptor, although the exact molecular details of its interaction are not well characterized."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1038","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPROZINOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:59:47.824390","biosimilars":[],"competitors":[{"drugName":"amlexanox","drugSlug":"amlexanox","fdaApproval":"1996-12-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"omalizumab","drugSlug":"omalizumab","fdaApproval":"2003-06-20","relationship":"same-class"},{"drugName":"roflumilast","drugSlug":"roflumilast","fdaApproval":"2011-02-28","patentExpiry":"Jun 7, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"reslizumab","drugSlug":"reslizumab","fdaApproval":"2016-03-23","relationship":"same-class"},{"drugName":"mepolizumab","drugSlug":"mepolizumab","fdaApproval":"2015-11-04","relationship":"same-class"},{"drugName":"benralizumab","drugSlug":"benralizumab","fdaApproval":"2017-11-17","relationship":"same-class"},{"drugName":"tezepelumab","drugSlug":"tezepelumab","fdaApproval":"2021-12-17","relationship":"same-class"}],"genericName":"eprozinol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amlexanox","brandName":"amlexanox","genericName":"amlexanox","approvalYear":"1996","relationship":"same-class"},{"drugId":"omalizumab","brandName":"omalizumab","genericName":"omalizumab","approvalYear":"2003","relationship":"same-class"},{"drugId":"roflumilast","brandName":"roflumilast","genericName":"roflumilast","approvalYear":"2011","relationship":"same-class"},{"drugId":"reslizumab","brandName":"reslizumab","genericName":"reslizumab","approvalYear":"2016","relationship":"same-class"},{"drugId":"mepolizumab","brandName":"mepolizumab","genericName":"mepolizumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"benralizumab","brandName":"benralizumab","genericName":"benralizumab","approvalYear":"2017","relationship":"same-class"},{"drugId":"tezepelumab","brandName":"tezepelumab","genericName":"tezepelumab","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"004183","UNII":"IJ21AK8IVJ","CHEBI":"CHEBI:135497","INN_ID":"2675","RXNORM":"24274","UMLSCUI":"C0059471","ChEMBL_ID":"CHEMBL2107691","KEGG_DRUG":"D07379","DRUGBANK_ID":"DB13395","PUBCHEM_CID":"122553","MESH_SUPPLEMENTAL_RECORD_UI":"C015853"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":6,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"R03DX02","allCodes":["R03DX02"]},"biosimilarFilings":[],"recentPublications":[{"date":"1985 Jun","pmid":"4026148","title":"[Convulsions with 3 antitussive substituted derivatives of piperazine (zipeprol, eprazinone, eprozinol)].","journal":"Annales de pediatrie"},{"date":"1981","pmid":"7312935","title":"Mechanisms of anti-bronchoconstrictive effects of eprozinol. II. In vivo studies on the guinea pig.","journal":"Pharmacology"},{"date":"1981","pmid":"6171839","title":"Mechanisms of anti-bronchoconstrictive effects of eprozinol. I. In vitro studies.","journal":"Pharmacology"},{"date":"1978 Jul-Aug","pmid":"756799","title":"[Eprozinol treatment of chronic bronchitis with dyspnea and cough].","journal":"Broncho-pneumologie"},{"date":"1977 Aug","pmid":"21982","title":"Dualist or pseudo-dualist interactions of mepyramine, diphenhydramine and eprozinol with histamine at H1-receptors.","journal":"Japanese journal of pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eprozinol is a small molecule drug of the eprozinol class, but specific details about its target and mechanism of action are unknown. It is not clear if it has been approved by the FDA or if it is commercially available. Eprozinol's indications, half-life, bioavailability, and generic manufacturers are also unknown. As a result, there is limited information available about this compound. Further research is needed to understand its clinical utility and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}